Skip to content

Standardisation of Investigations of Mild Bleeding Disorders

Standardisation of Investigations of Mild Bleeding Disorders

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02329899
Acronym
MBD
Enrollment
208
Registered
2015-01-01
Start date
2012-07-31
Completion date
2016-09-30
Last updated
2016-11-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hemorrhagic Disorders

Brief summary

Observational study aimed at evaluating the clinical impact of a standardised diagnostic procedure for the investigation of patients with suspected mild bleeding disorder (MBD).

Detailed description

The working hypothesis of this prospective diagnostic study is that a standardised procedure in investigating patients with suspected MBD will lead to a better discrimination between patients with and without MBD and a more precise characterisation of MBD. The primary objective of this diagnostic study is to evaluate the efficiency of a standardised procedure of MBD in children and adults referred to their respective outpatient clinics for bleeding symptoms. The following endpoints will be evaluated: 1. The relative number of precise diagnosis (according to recognised classification of haemostatic disorders) in each clinical probability category; 2. The number of biological tests performed per patient in each clinical probability category; 3. The relative number of patients with no specialised investigations in the low risk group. The secondary objective is to evaluate the bleeding events during a one-year follow-up. Follow-up will be performed with a phone call one year after the last consultation of the patient. The definition of a bleeding event will be any bleeding that promotes any specific medical attention (consultation, hospitalisation, transfusion, re-intervention in case of surgery). The detailed clinical history regarding each event will be collected. Bleeding events will be correlated to the clinical probability assessed at inclusion.

Interventions

OTHERSecond step of investigations

Second step according to results of the first step: * exploration of coagulation factors; * factor XIII and fibrinolysis investigations; * investigation of platelet function; * investigation of thrombocytopenia.

Sponsors

University Hospital, Geneva
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
2 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* All patients aged more than two years-old referred by their physician (gynaecologist, paediatrician, general practitioner, surgeon, etc.) for investigations of a possible bleeding tendency will be included in this study. This prospective study will include consecutive patients attending the four outpatient clinics (Division of Angiology and Haemostasis and Paediatric Onco-Haematology Unit, University Hospitals of Geneva).

Exclusion criteria

* Pregnant women will be excluded because of modifications of the known modifications of the haemostasis system during pregnancy. Adult patients without discernment capacity will be excluded.

Design outcomes

Primary

MeasureTime frameDescription
Relative number of precise diagnosisafter the completion of the standardized diagnostic procedure (on average 6 weeks after enrollment)Diagnosis are going to be evaluated according to recognized classification of haemostatic disorders
Number of biological tests performed per patientafter the completion of the standardized diagnostic procedure (on average 6 weeks after enrollment)
Relative number of patients with no specialised investigations in the low risk groupafter the completion of the standardized diagnostic procedure (on average 1 week after enrollment in this low risk group)

Secondary

MeasureTime frameDescription
Evaluation of bleeding eventsAfter one year follow-upPhone call

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026